Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Pulmonary Diseases

Treatment of Pulmonary Hypertension in Premature Neonates

: Live Program
Pulmonary Diseases
: 1.5 AMA PRA Category 1 Credit(s)™
Target Audience
: Healthcare providers who care for premature neonates with pulmonary hypertension
Expiration Date
: 04/29/2019

Read the content below to launch the activity

Register now!

Please join us for an Industry-Sponsored Symposium at PAS 2019
Treatment of Pulmonary Hypertension in Premature Neonates
This activity is supported by an independent educational grant from Mallinckrodt Pharmaceuticals

Monday, April 29, 2019
Registration/Breakfast: 5:30 am – 6:15 am
Scientific Program: 6:15 am – 7:45 am

Hilton Key Ballroom 7, 2nd Floor
Hilton Baltimore
401 West Pratt Street
Baltimore, MD

Activity Overview

Preterm neonates with pulmonary hypertension (PH) suffer from very serious derangement of the cardiopulmonary circulation due to pulmonary vascular resistance and hypoxemia. Persistent neonatal PH is associated with mortality that ranges from 4% to 33% in various studies, and neurological impairment in 15%-25% of infants. In the past 20 years, scientific research has led to an increased understanding of the cellular responses by the remodeled vasculature in PH, which may in turn uncover new signaling pathways and herald the discovery of new therapeutic targets. A primary goal of this CME-certified program is to help pediatricians distinguish between PH, cyanotic heart lesions, and other cardiopulmonary diseases which may share a similar clinical phenotype but have diverse pathophysiologic contributors. In addition, the severe pathophysiologic changes in the pulmonary circulation together with the effects of positive pressure ventilation used in PH can profoundly affect heart-lung interactions. This symposium will provide insights on the physiologic interactions between abnormal respiratory and CV function in PH, methods to reduce RV afterload, the use of selective pulmonary vasodilators and lung-protective mechanical ventilation to ameliorate the long-term effects of PH. Finally, our expert faculty will assess the clinical evidence from early studies of experimental treatments for PH in neonates which may eventually lead to a therapeutic advantage against this life-threatening disease.

Educational Objectives

Upon completion of this activity, participants should be able to:

1. Discuss the pathophysiologic contributors to and recognize the risk factors for PH in premature neonates to facilitate earlier diagnosis and prevention.

2. Optimize ventilator management for premature neonates with PH to enhance ventilation-perfusion matching and pulmonary gas exchange.

3. Administer pharmacologic treatments for PH in neonates to induce pulmonary vasorelaxation and improve both pulmonary perfusion and right heart function.


Leif D. Nelin, MD
Program Chair
Dean Jeffers Endowed Chair in Neonatology
Professor, Department of Pediatrics
The Ohio State University College of Medicine
The Research Institute at Nationwide Children’s Hospital
Columbus, OH

Steven H. Abman, MD
Professor, Department of Pediatrics
Section of Pulmonology
University of Colorado School of Medicine
Director, Pediatric Heart Lung Center
Children’s Hospital Colorado
Aurora, CO

John P. Kinsella, MD
Professor, Department of Pediatrics
Section of Neonatology
University of Colorado School of Medicine
and Children’s Hospital Colorado
Aurora, CO